DDR1 and Alzheimer disease: Importantly, miRNA data demonstrate reduction of chemokines and cytokines and other inflammatory markers in the CSF of nilotinib-treated AD patients compared to placebo suggesting reduction of inflammation, in agreement with pre-clinical data that show DDR1 inhibition stimulates clearance of neurotoxic proteins via autophagy and reduces inflammation in animal models of neurodegeneration [18, 22, 25, 26, 30].